Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tildrakizumab on Coronary Microvascular Function in Psoriasis
NCT04271540Phase 4Completed
- Sponsor
- Marcelo F. Di Carli
- Start
- Apr 2020
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label trial of tildrakizumab in psoriasis, sponsored by Marcelo F. Di Carli. Primary endpoint: Global Coronary Flow Reserve at 24 weeks. Started Apr 2020; status: completed.
02
Drugs
tildrakizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT04271540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04271540.